226 results on '"Pytowski, Bronislaw"'
Search Results
2. Pulmonary Lymphangiectasia Resulting From Vascular Endothelial Growth Factor-C Overexpression During a Critical Period
3. Correction: Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human antihuman VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C
4. Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers
5. Supplemental Figures 1 through 9 and Supplemental Tables 1 and 2 from Stromal-Based Signatures for the Classification of Gastric Cancer
6. Supplemental Figure Legends from Stromal-Based Signatures for the Classification of Gastric Cancer
7. Supplemental Methods from Stromal-Based Signatures for the Classification of Gastric Cancer
8. Supplemental Figures from Stromal-Based Signatures for the Classification of Gastric Cancer
9. Data from Stromal-Based Signatures for the Classification of Gastric Cancer
10. Data from Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis
11. Supplementary Figure 1 from Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth
12. Supplementary Figure 1 from Suppression of Prostate Cancer Nodal and Systemic Metastasis by Blockade of the Lymphangiogenic Axis
13. Supplementary Table 1 from Vascular Endothelial Growth Factor Receptor 3 Is Involved in Tumor Angiogenesis and Growth
14. Hematopoietic Activity of a Stromal Cell Transmembrane Protein Containing Epidermal Growth Factor-Like Repeat Motifs
15. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
16. Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
17. Therapeutic Targeting of the Lymphovascular System in Cancer: Promise and Challenge
18. Lymphatic System in the Pathology of Cancer
19. Anti-VEGF Agents Confer Survival Advantages to Tumor-Bearing Mice by Improving Cancer-Associated Systemic Syndrome
20. Nonvascular VEGF Receptor 3 Expression by Corneal Epithelium Maintains Avascularity and Vision
21. Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model
22. Mutagenesis of the Human Transferrin Receptor: Two Cytoplasmic Phenylalanines Are Required for Efficient Internalization and a Second-Site Mutation Is Capable of Reverting an Internalization-Defective Phenotype
23. Fc and C3bi Receptors and the Differentiation Antigen BH2-Ag Are Randomly Distributed in the Plasma Membrane of Locomoting Neutrophils
24. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling
25. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation
26. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
27. The resolution of lymphedema by interstitial flow in the mouse tail skin
28. Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents
29. Regulation of lymphatic capillary regeneration by interstitial flow in skin
30. cDNA cloning, chromosomal mapping, and expression analysis of human VE-Cadherin-2
31. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy
32. Inhibition of lymphangiogenesis and lymphatic drainage via vascular endothelial growth factor receptor 3 blockade increases the severity of inflammation in a mouse model of chronic inflammatory arthritis
33. Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Functions to Promote Uterine Decidual Angiogenesis during Early Pregnancy in the Mouse
34. Blockade of Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Suppresses both Lymphatic and Blood Vessel Growth in the Inflamed Cornea: Poster No.: CN-D2-104 Panel No.: 104
35. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody
36. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation
37. Complete and Specific Inhibition of Adult Lymphatic Regeneration by a Novel VEGFR-3 Neutralizing Antibody
38. Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy
39. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity
40. Blockade of vascular endothelial growth factor receptor-1 (Flt-1), reveals a novel analgesic for osteoarthritis-induced joint pain
41. VEGF-C promotes the development of lymphatics in bone and bone loss
42. Author response: VEGF-C promotes the development of lymphatics in bone and bone loss
43. Vascular and tumor cell expression of VEGFR2 and molecular subtyping: An innovative biomarker approach in bladder cancer.
44. Pulmonary Lymphangiectasia Resulting from Vegf-C Overexpression During a Critical Period
45. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents
46. Abstract 930: Combined inhibition of pan-RAF and VEGFR-2 mediates antitumor activity in KRAS mutant non-small cell lung cancer (NSCLC) through enhanced inhibition of tumor angiogenesis and growth
47. Stromal-Based Signatures for the Classification of Gastric Cancer
48. Phase I study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody (mab) LY3022856/IMC-3C5 (3C5).
49. Inhibition of lymphangiogenesis and lymphatic drainage via VEGFR-3 blockade increases the severity of inflammation in chronic inflammatory arthritis
50. Fc AND C3 RECEPTORS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.